TY - JOUR
T1 - “To Anticipate”
T2 - Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers
AU - Garutti, Mattia
AU - Buriolla, Silvia
AU - Bertoli, Elisa
AU - Vitale, Maria Grazia
AU - Rossi, Ernesto
AU - Schinzari, Giovanni
AU - Minisini, Alessandro Marco
AU - Puglisi, Fabio
N1 - Funding Information:
Funding: This work was supported by the Italian Ministry of Health (Ricerca Corrente) (no grant number provided).
Funding Information:
Conflicts of Interest: The authors declare no conflict of interest regarding this work. Alessandro Marco Minisini, reports an advisory role for Novartis, MSD, Pierre Fabre. Fabio Puglisi, reports grants from AstraZeneca, grants, personal fees and others from Roche, personal fees and others from Eli Lilly, personal fees from Amgen, personal fees from Ipsen, personal fees from MSD, personal fees from Takeda, grants and others from Eisai, others from Novartis, and others from Pfizer, outside the submitted work.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/7
Y1 - 2020/7
N2 - Despite surgical resection and adjuvant therapies, stage III melanomas still have a substantial risk of relapse. Neoadjuvant therapy is an emerging strategy that might offer superior efficacy compared to adjuvant therapy. Moreover, neoadjuvant therapy has some virtual advantages: it might allow for less demolitive surgery, permit the in vivo evaluation of drug efficacy, help tailor adjuvant treatments, and play a crucial role in innovative translational research. Herein, we review the available literature to explore the scientific background behind the neoadjuvant approach. We also discuss published clinical trials with a focus on predictive biomarkers and ongoing studies. Finally, we outline a possible framework for future neoadjuvant clinical trial development based on the International Neoadjuvant Melanoma Consortium guidelines.
AB - Despite surgical resection and adjuvant therapies, stage III melanomas still have a substantial risk of relapse. Neoadjuvant therapy is an emerging strategy that might offer superior efficacy compared to adjuvant therapy. Moreover, neoadjuvant therapy has some virtual advantages: it might allow for less demolitive surgery, permit the in vivo evaluation of drug efficacy, help tailor adjuvant treatments, and play a crucial role in innovative translational research. Herein, we review the available literature to explore the scientific background behind the neoadjuvant approach. We also discuss published clinical trials with a focus on predictive biomarkers and ongoing studies. Finally, we outline a possible framework for future neoadjuvant clinical trial development based on the International Neoadjuvant Melanoma Consortium guidelines.
KW - Adjuvant
KW - BRAF
KW - Immunotherapy
KW - MEK
KW - Melanoma
KW - Neoadjuvant
UR - http://www.scopus.com/inward/record.url?scp=85088412916&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088412916&partnerID=8YFLogxK
U2 - 10.3390/cancers12071941
DO - 10.3390/cancers12071941
M3 - Review article
VL - 12
SP - 1
EP - 19
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 7
M1 - 1941
ER -